8 studies on ARA-290 curated from PubMed, ClinicalTrials.gov, and EuropePMC. Updated daily.
Bottom line: TitrateLab indexes 568 published ARA-290 COA source records from third-party laboratories, covering 261 publicly attributable vendor identities. Across 525 records with positive numeric purity, the arithmetic mean is 99.02%. 0 records report zero purity; these remain in the record count and are excluded from the positive-purity mean. 8 positive purity results are below 90%; 11 records report measured amount more than 10% below the label. The latest recorded test date is 2026-10-15. TitrateLab did not perform these laboratory tests. Source records are not unique batches, and vendor identity does not establish manufacturing role, product safety or overall quality.
As of 2026-10-18, vendor-blind retail asking-price averages for the US delivery market, calculated from the same in-stock exact-strength cells as the Peptide Price Index. Shipping is excluded.
| Strength | Average / vial | Observed range / vial | Average / mg | Coverage |
|---|---|---|---|---|
| 10 mg | $10.00 | $10.00–$10.00 | $1.00 | 1 source · 1 offer |
| 16 mg | $14.00 | $14.00–$14.00 | $0.88 | 1 source · 1 offer |
Asking prices are not manufacturing cost and do not establish product equivalence, quality, safety, or legality. View full price methodology →
All published source records, including absent and zero purity. Matching uses a case-insensitive exact peptide token. No deduplication in the headline; vendor rankings deduplicate eligible certificates separately. The COA archive can use normalized compound names and a different measurement or duplicate policy; totals from these populations need not match.
Latest recorded test: 2026-10-15. Aggregate calculated: 2026-10-18T07:20:56.205410+00:00. Calculation time is not a laboratory observation date.
Within that total, 174 source records have unresolved vendor identity. They remain in corpus-level lab evidence and are excluded from named-vendor rankings.
Eligible vendors have at least 2 deduplicated certificates and 2 classifiable identity observations. Rank uses the 95% lower confidence bound on clean identity results; mean positive purity and certificate count break ties. Missing measurements are not passes. Exact-zero/not-detected and explicit wrong-compound markers count once per adverse certificate. This describes submitted-sample evidence, not every product or shipment, and is not an endorsement.
| Rank | Vendor | Deduplicated certificates | Avg positive purity | Identity adverse results | |
|---|---|---|---|---|---|
| #1 | 20 | 99.13% | 0 of 19 (0.0%) 0 0% / not detected · 0 wrong compound · 1 unclassified | Reveal with Pro → | |
| #2 | 10 | 98.09% | 0 of 10 (0.0%) 0 0% / not detected · 0 wrong compound | Reveal with Pro → | |
| #3 | 5 | 99.79% | 0 of 5 (0.0%) 0 0% / not detected · 0 wrong compound | Reveal with Pro → |
Vendor identities are included with Pro. Record counts and lab measurements remain visible.
Recent source records: #120460 (99.72%) · #120185 (99.41%) · #120161 (99.72%) · #120133 (99.89%) · #119054 (99.21%) · #118864 (99.84%)
This comprehensive review consolidates critical knowledge on tissue-protective cytokines, particularly EPO, making it a valuable resource for researchers and clinicians. The detailed experimental protocols included in…
**The findings suggest a potential preventative strategy for early-stage Alzheimer's, where ARA 290 could be used to modulate the immune system before significant pathology is established.** For biohackers or clinicia…
These findings propose ARA-290 as a potential adjunctive therapy to mitigate the severe side effects of doxorubicin, a cornerstone of many cancer treatments. For patients undergoing chemotherapy, this could mean reduc…
The exploration of ARA 290, a non-hematopoietic erythropoietin analogue, holds significant promise as it targets a novel mechanism for glucose regulation, potentially offering a new therapeutic avenue beyond existing …
If the study's hypothesis of a positive shift in emotional processing was confirmed, it would represent a significant step forward in neuroscience and psychopharmacology. This could establish ARA290 as a promising can…
Free, no account — handy when you're working with ARA-290.
Pro members save studies and unlock the full evidence breakdown and vendor lab data.
Buyer protection: Wrong or defective product? Report it within 7 days. We broker a refund or reship with the vendor.
$14 monthly or $88/year
Create an account